Lenzetto (Estradiol Hemihydrate)

Lenzetto, an estrogen transdermal system, is used to manage conditions related to estrogen deficiency.

• Menopausal vasomotor symptoms: reduction of hot flashes and night sweats.
• Postmenopausal osteoporosis: prevention of bone loss and fracture risk.
• Hypoestrogenism: restoration of normal estrogen levels in women with deficient endogenous production.

• Estradiol hemihydrate acts as an agonist at estrogen receptors (ERα and ERβ) in target tissues. Binding to these nuclear receptors modulates transcription of estrogen‑responsive genes, leading to restoration of estrogen‑dependent physiological processes such as thermoregulation, bone remodeling, and maintenance of the urogenital mucosa. The transdermal delivery bypasses first‑pass metabolism, providing stable systemic concentrations.

Common Side Effects

• Skin irritation at the application site: redness, itching, or rash.
• Breast tenderness: mild discomfort or swelling.
• Headache: transient episodes of mild to moderate intensity.
• Nausea: occasional upset stomach or feeling of queasiness.
• Bloating: abdominal distension or mild discomfort.
• Mood changes: irritability or mild emotional fluctuations.

Serious or Rare Side Effects

• Thromboembolic events: deep vein thrombosis or pulmonary embolism.
• Stroke or transient ischemic attack: neurological deficits due to vascular occlusion.
• Myocardial infarction: heart attack in susceptible individuals.
• Gallbladder disease: formation of gallstones or cholecystitis.
• Hepatic dysfunction: abnormal liver enzymes or jaundice.
• Breast cancer risk: potential increase with long‑term use.

Before initiating therapy, evaluate patient history and risk factors.

• Cardiovascular assessment: review history of thromboembolism, stroke, or myocardial infarction.
• Breast evaluation: perform clinical exam and consider imaging for women with a personal or family history of breast cancer.
• Liver function: check baseline hepatic enzymes in patients with known liver disease.
• Bone health monitoring: assess bone mineral density periodically in long‑term users.
• Concomitant estrogen use: avoid combining with other systemic estrogen products.
• Store at room temperature: keep below 25°C, protect from moisture and direct sunlight, and retain in the original pouch until application.

Estradiol hemihydrate may interact with several drug classes.

Major Interactions (Avoid)

• Combined hormonal contraceptives: additive risk of thromboembolic events.
• Selective estrogen receptor modulators (e.g., tamoxifen): antagonistic pharmacodynamic effect.
• Antifungal azoles (e.g., ketoconazole): may increase estradiol plasma concentrations.

Moderate Interactions (Monitor Closely):\n- CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce estradiol exposure.

• Anticoagulants (e.g., warfarin): potential alteration of INR, requiring closer monitoring.
• SSRIs/SNRIs (e.g., paroxetine, venlafaxine): may diminish relief of vasomotor symptoms.
• Thyroid hormone replacement: may affect estradiol metabolism, necessitating dose review.